Counting the cost of meningococcal disease: Scenarios of severe meningitis and septicemia

Pediatric Drugs

Volumn 15, Issue 1, 2013, Pages 49-58

  Wright, Claire ^a   Wordsworth, Rebecca ^a   Glennie, Linda ^a  

^a Meningitis Research Foundation   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE DISEASE; ARTICLE; BUDGET; CHILD; CLINICAL ARTICLE; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; EPIDEMIC MENINGITIS; GOVERNMENT; HEALTH CARE COST; HEALTH EDUCATION; HEALTH SERVICE; HUMAN; IMMUNIZATION; INFANT; MEDICAL LITERATURE; MENINGOCOCCOSIS; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; REHABILITATION CARE; SEPTICEMIA; SOCIAL CARE; SURVIVOR; UNITED KINGDOM;

ANALYSIS OF VARIANCE; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; GREAT BRITAIN; HUMANS; MENINGITIS, MENINGOCOCCAL; SEPSIS;

EID: 84873369683     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-012-0006-0     Document Type: Article

References (24)

1. NICE. Bacterial meningitis and meningococcal septicaemia in children. Full guideline 2010. Available from URL: http://www.nice.org.uk/nicemedia/live/ 13027/49437/49437.pdf. Accessed 18 Dec 2012.
2. Edmond K, et al. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(5):317-28.
3. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis. 1998;26(5):1159-64.
4. Canavese F, Krajbich JI, LaFleur BJ. Orthopaedic sequelae of childhood meningococcemia: management considerations and outcome. J Bone Joint Surg Am. 2010;92(12):2196-203.
5. Hall AJ. The United Kingdom Joint Committee on Vaccination and Immunisation. Vaccine. 2010;28(Suppl 1):A54-7.
6. Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ. 2002;324:809.
7. Scottish Intercollegiate Guidelines Network. Management of invasive meningococcal disease in children and young people. Edinburgh: Scottish Intercollegiate Guidelines Network; 2008.
8. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. 2004. Available from URL: http://www.nice.org.uk/ niceMedia/pdf/TAP-Methods.pdf. Accessed 9 Dec 2010.
9. Ten Jonsson B. Arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357-9.
10. Treasury HM. The green book: appraisal and evaluation in central government. London: TSO; 2003.
11. Office for National Statistics. Interim life tables, 2007-2009. Available from URL: http://www.ons.gov.uk/ons/publications/re-reference-tables.html? edition=tcm%3A77-61850. Accessed 14 Dec 2010.
12. Buysse CM, et al. Long-term health status in childhood survivors of meningococcal septic shock. Arch Pediatr Adolesc Med. 2008;162(11):1036-41.
13. Department of Health. National schedule of reference costs 2008-09 for NHS trusts and PCTs combined. Available from URL: http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-111591. Accessed 4 Oct 2010.
14. Curtis L. Unit costs of health and social care 2009. Available from URL: http://www.pssru.ac.uk/project-pages/unit-costs/2009/index.php. Accessed 21 Dec 2012.
15. Holmes L, McDermid S, Sempik J. The costs of short break provision. Available from URL: http://www.ccfcs.org.uk/Documents/Publications/ ShortBreaksDCSF.pdf. Accessed 6 Dec 2010.
16. British National Formulary, 2010. Available from URL: http://bnf.org/bnf/bnf/60/3914.htm#-3914. Accessed 7 Dec 2010.
17. British National Formulary for Children, 2010. Available from URL: http://bnfc.org/bnfc/bnfc/current/3914.htm#-3914. Accessed 7 Dec 2010.
18. Christensen H, et al. Modelling the potential impact of new menB vaccines in England allowing for herd immunity. EMGM Book of Abstracts 2011. Available from URL: http://emgm.eu/meetings/emgm2011/abstracts.pdf. Accessed 21 Dec 2012.
19. Welte R, et al. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics. 2005;23(9):855-74.
20. Copps J, Heady L. What price an ordinary life? The financial costs and benefits of supporting disabled children and their families. Available from URL: http://www.philanthropycapital.org/publications/health/disabled-children/ disabled-children-cost.aspx. Accessed 21 Dec 2010.
21. Dobson B, Middleton S. Paying to care: the cost of childhood disability. Joseph Rowntree Foundation, 1998. Available from URL: http://www.jrf.org.uk/ publications/paying-care-cost-childhood-disability. Accessed 21 Dec 2012.
22. Gordon D, Parker R, Loughran F, Heslop P. Disabled children in Britain: a re-analysis of the OPCS disability survey. London: The Stationery Office; 2000.
23. Cadman D, Boyle M, Offord DR. The Ontario Child Health Study: social adjustment and mental health of siblings of children with chronic health problems. J Dev Behav Pediatr. 1988;9(3):117-21.
24. Viner RM, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774-83.